ReviewCurrent psychiatry reports2019
Phenibut (β-Phenyl-γ-Aminobutyric Acid): an Easily Obtainable "Dietary Supplement" With Propensities for Physical Dependence and Addiction.
Review in Current psychiatry reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 31 citations in OpenAlex.
- Pediatricians' psychopharmacological practice: a pilot survey in Poland and Ukraine.BMC primary care · 2026Article
- Phenibut: A drug with one too many "buts".Basic & clinical pharmacology & toxicology · 2024Review
- Phenibutan—an Illegal Food Supplement With Psychotropic Effects and Health Risks.Deutsches Arzteblatt international · 2024Review
- A Case of Phenibut Withdrawal Management and Detoxification Using Baclofen in the Outpatient Setting.Case reports in psychiatry · 2024Article
- A case of phenibut withdrawal and treatment with baclofen.World journal of emergency medicine · 2023Article
- GABACurrent topics in behavioral neurosciences · 2022Review
- When an obscurity becomes trend: social-media descriptions of tianeptine use and associated atypical drug use.The American journal of drug and alcohol abuse · 2021Article
- Psychomotor Agitation Non-responsive to Treatment: A Case Report of Phenibut Withdrawal Syndrome.Frontiers in psychiatry · 2021Article
- Notes from the Field: Phenibut Exposures Reported to Poison Centers - United States, 2009-2019.MMWR. Morbidity and mortality weekly report · 2020Article
- Interpol review of controlled substances 2016-2019.Forensic science international. Synergy · 2020Review
- Article
- A Case of Phenibut Directed Detoxification Leading to Toxicity During the COVID-19 Pandemic.Journal of addiction medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewPhenibut (β-phenyl-γ-aminobutyric acid) is a psychoactive GABA analogue currently being marketed online as an anxiolytic and nootropic dietary supplement. Its use is growing in popularity, but its pharmacological activity is well beyond that of a conventional nutritional supplement, and similar to that of a prescription strength sedative. This review will focus on the potential adversities of phenibut use and will discuss what treatment options may be beneficial to afflicted patients. RECENT
findingsOver the last several years, multiple case reports have highlighted phenibut's potential to produce the conditions of physical dependence, withdrawal, and addiction. In cases involving intoxication, patients have presented with a varying degree of mental status changes, from being minimally responsive to manifesting symptoms of an agitated delirium. Phenibut is a potent psychoactive substance with GABA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.